(Q34558148)

3 August 2017

1 reference

title

Radiotherapy and combined modality approaches in localised prostate cancer (English)

1 reference

Adaptive radiation therapy

3 August 2017

main subject

0 references

1 reference

Dearnaley DP

1

1 reference

3 August 2017

language of work or name

1 reference

1 October 2001

1 reference

European Journal of Cancer

3 August 2017

published in

1 reference

3 August 2017

volume

37 Suppl 7

1 reference

3 August 2017

page(s)

S137-45

1 reference

Early prostate cancer--to treat or not to treat?

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Population-based study of long-term survival in patients with clinically localised prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of > 4-20 ng/ml

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Incidental carcinoma of the prostate: an analysis of the predictors of progression

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Results of conservative management of clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Clinical relevance of trans-rectal ultrasound, biopsy, and serum prostate-specific antigen following external beam radiotherapy for carcinoma of the prostate.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Carcinoma of the prostate: results of post-irradiation biopsy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Patterns-of-failure analysis of patients with high pretreatment prostate-specific antigen levels treated by radiation therapy: the need for improved systemic and locoregional treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Conformal technique dose escalation for prostate cancer: Biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen ≥10 ng/ml

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

The correlation of serial prostate specific antigen measurements with clinical outcome after external beam radiation therapy of patients for prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Carcinoma of the prostate: results of radical radiotherapy (1970-1985).

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Adenocarcinoma of the prostate treated with external-beam radiation therapy: 5-year minimum follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

External beam radiotherapy for carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Stage C adenocarcinoma of the prostate. An analysis of 551 patients treated with external beam radiation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

External beam radiotherapy in cancer of the prostate. The University of Arizona experience

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Improving the therapeutic ratio of external beam irradiation for carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Patterns of care outcome studies: results of the national practice in adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

A ten year follow-up of 682 patients treated for prostate cancer with radiation therapy in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

The outcome of treatment of 313 patients with T-1 (UICC) prostate cancer treated with external beam irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Acute side effects and late complications after radiotherapy of localized carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

A pilot survey of sexual function and quality of life following 3D conformal radiotherapy for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Quality-of-life outcomes in men treated for localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Complications after treatment with external-beam irradiation in early-stage prostate cancer patients: a prospective multiinstitutional outcomes study.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Self-assessment questionnaire for evaluating urinary and intestinal late side effects after pelvic radiotherapy in patients with prostate cancer compared with an age-matched control population

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

The effect of dose on local control of prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Dose escalation for stage C (T3) prostate cancer: minimal rectal toxicity observed using conformal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

3D conformal radiation therapy (3DCRT) for high grade prostate cancer: a multi-institutional review

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Target volume definition in conformal radiotherapy for prostate cancer: quality assurance in the MRC RT-01 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumor system

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Neoadjuvant hormonal downsizing of localized carcinoma of the prostate: effects on the volume of normal tissue irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Treatment of advanced localised prostatic cancer by orchiectomy, radiotherapy, or combined treatment. A Medical Research Council Study. Urological Cancer Working Party--Subgroup on Prostatic Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2980015-0

7 January 2021

10.1016/S0959-8049(01)80015-0

Identifiers

DOI

1 reference

3 August 2017

1 reference